Key result
Benidipine increased flow-mediated dilatation from 4.7% to 7.4% in patients with coronary vasospasm, whereas diltiazem and verapamil had no effect.
Why the study?
Does benidipine improve vascular endothelial function compared to diltiazem or verapamil in patients with coronary spastic angina?
RCT (n=25)
Randomized
Does benidipine improve vascular endothelial function compared to diltiazem or verapamil in patients with coronary spastic angina?
In patients with coronary spastic angina, the dihydropyridine calcium-channel blocker benidipine significantly improved endothelial function and increased NO production, unlike the non-dihydropyridines diltiazem or verapamil.
Answers are grounded in this paper and cite their sources.
Benidipine may be preferred over diltiazem or verapamil in coronary vasospasm; extends evidence for differential endothelial effects among calcium-channel blockers.
BACKGROUND: The effects of the 3 classes of L-type calcium-channel blockers (CCBs) on vascular endothelial function have not been clarified in patients with coronary vasospasm. METHODS AND RESULTS: Twenty-five normotensive patients (age 64.0+/-1.4 years) with coronary vasospasm were randomly treated for 3 months with benidipine, diltiazem, and verapamil, which belong to the dihydropyridine, benzothiazepine, and phenylalkylamine classes of CCBs, respectively. Endothelium-dependent flow-mediated dilatation (FMD), endothelium-independent nitroglycerin-induced dilatation in the brachial arteries, and plasma cyclic guanosine 3',5'-monophosphate (cGMP), a nitric-oxide-related product, were assessed before and after treatment. At baseline, the patients with vasospasm had significantly lower FMD as compared with normal subjects (n=8). Blood pressure did not differ among the 3 groups before and after treatment. Benidipine significantly increased FMD (from 4.7+/-0.6 to 7.4+/-1.1%, P<0.05) and plasma cGMP levels. In contrast, neither diltiazem nor verapamil affected FMD and cGMP levels. None of the treatments affected nitroglycerin-induced dilatation. CONCLUSIONS: Benidipine, but not diltiazem or verapamil, improves endothelial dysfunction beyond blood pressure lowering effects in patients with coronary vasospasm. Upregulation of the nitric oxide - cGMP system by benidipine may partly contribute to the improvement. The dihydropyridine class may be more beneficial for vascular endothelial function than the non-dihydropyridine classes of CCBs.
No takes yet. Share an insight, caveat, or question.
Miwa et al. (2009) conducted an RCT in Coronary spastic angina (n=25). Benidipine vs. Diltiazem and verapamil was evaluated on Endothelium-dependent flow-mediated dilatation (FMD) (p=<0.05). Benidipine increased flow-mediated dilatation from 4.7% to 7.4% in patients with coronary vasospasm, whereas diltiazem and verapamil had no effect.
Synapse has enriched 10 related papers. Consider them for comparative context: